The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy
Open accessAbstract
Background: Recent studies have reported weight gain in virologically suppressed persons living with human immunodeficiency virus (PLWH) switched from older antiretroviral therapy (ART) to newer integrase strand transfer inhibitor (INSTI)–based regimens. In this study, we investigated whether weight gain differs among treatment-naive PLWH starting INSTI-based regimens compared to other ART regimens. Methods: Adult, treatment-naive PLWH in the Vanderbilt Comprehensive Care Clinic cohort initiating INSTI-, protease inhibitor (PI)–, and nonnucleoside reverse transcriptase inhibitor (NNRTI)–based ART between January 2007 and June 2016 were included. We used multivariable linear mixed-effects models to generate marginal predictions of weights over time, adjusting for baseline clinical and demographic characteristics. We used restricted cubic splines to relax linearity assumptions and bootstrapping to generate 95% confidence intervals. Results: Among 1152 ART-naive PLWH, 351 initiated INSTI-based regimens (135 dolutegravir, 153 elvitegravir, and 63 raltegravir), 86% were male, and 49% were white. At ART initiation, median age was 35 years, body mass index was 25.1 kg/m2, and CD4+ T-cell count was 318 cells/μL. Virologic suppression at 18 months was similar between different ART classes. At all examined study time points, weight gain was highest among PLWH starting dolutegravir. At 18 months, PLWH on dolutegravir gained 6.0 kg, compared to 2.6 kg for NNRTIs (P < .05), and 0.5 kg for elvitegravir (P < .05). PLWH starting dolutegravir also gained more weight at 18 months compared to raltegravir (3.4 kg) and PIs (4.1 kg), though these differences were not statistically significant. Conclusions: Treatment-naive PLWH starting dolutegravir-based regimens gained significantly more weight at 18 months than those starting NNRTI-based and elvitegravir-based regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV Infection and the Risk of Acute Myocardial Infarction
Freiberg, M. S., Chang, C.-C. H., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., Butt, A. A., Bidwell Goetz, M., Leaf, D., Oursler, K. A., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3728 · Cited by 1,340
Schouten, J., Wit, F. W., Stolte, I. G., Kootstra, N. A., van der Valk, M., Geerlings, S. E., Prins, M., Reiss, P., for the AGEhIV Cohort Study Group, Reiss, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu701 · Cited by 752
Koethe, J. R., Jenkins, C. A., Lau, B., Shepherd, B. E., Justice, A. C., Tate, J. P., Buchacz, K., Napravnik, S., Mayor, A. M., Horberg, M. A., et al. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0147 · Cited by 337
Self-citationLang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., Boccara, F., Bingham, A., & Costagliola, D. (2010) · AIDS · doi:10.1097/qad.0b013e328339192f · Cited by 299
Norwood, J., Turner, M., Bofill, C., Rebeiro, P., Shepherd, B., Bebawy, S., Hulgan, T., Raffanti, S., Haas, D. W., Sterling, T. R., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001525 · Cited by 284
Self-citationJustman, J. E., Benning, L., Danoff, A., Minkoff, H., Levine, A., Greenblatt, R. M., Weber, K., Piessens, E., Robison, E., & Anastos, K. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200303010-00009 · Cited by 213
Paton, N., Sangeetha, S., Earnest, A., & Bellamy, R. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00383.x · Cited by 209
Weight Change After Antiretroviral Therapy and Mortality
Yuh, B., Tate, J., Butt, A. A., Crothers, K., Freiberg, M., Leaf, D., Logeais, M., Rimland, D., Rodriguez-Barradas, M. C., Ruser, C., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ192 · Cited by 202
Metabolic disease in HIV infection
Lake, J. E., & Currier, J. S. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70271-8 · Cited by 195
Herrin, M., Tate, J. P., Akgün, K. M., Butt, A. A., Crothers, K., Freiberg, M. S., Gibert, C. L., Leaf, D. A., Rimland, D., Rodriguez-Barradas, M. C., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001071 · Cited by 193
Cited by
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coelho, L., Cabello, R., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 900
HIV and cardiovascular disease
So-Armah, K., Benjamin, L. A., Bloomfield, G. S., Feinstein, M. J., Hsue, P., Njuguna, B., & Freiberg, M. S. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30036-9 · Cited by 313
Venter, W. D. F., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., Serenata, C., Akpomiemie, G., Masenya, M., Qavi, A., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30241-1 · Cited by 269
Bourgi, K., Jenkins, C. A., Rebeiro, P. F., Shepherd, B. E., Palella, F., Moore, R. D., Althoff, K. N., Gill, J., Rabkin, C. S., Gange, S. J., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25484 · Cited by 246
Self-citationObesity and weight gain in persons with HIV
Bailin, S. S., Gabriel, C. L., Wanjalla, C. N., & Koethe, J. R. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00483-5 · Cited by 213
Self-citation
Metadata
- Authors
- Bourgi, K., Rebeiro, P. F., Turner, M., Castilho, J. L., Hulgan, T., Raffanti, S. P., Koethe, J. R., & Sterling, T. R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-17
- Volume
- 70
- Issue
- 7
- Pages
- 1267-1274
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2945985905
- Cited by
- 327
- References
- 32
- FWCI
- 50.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. https://app.cochat.ai/papers/10.1093/cid/ciz407
- The paper
- Bourgi, K., Rebeiro, P. F., Turner, M., Castilho, J. L., Hulgan, T., Raffanti, S. P., Koethe, J. R., & Sterling, T. R. (2020). Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciz407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.